TrialDrug design, development and therapy2019

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers.

Wonsuk Shin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.